Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have been assigned a consensus recommendation of “Hold” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $51.75.

Several analysts have recently issued reports on PSTV shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Friday, July 17th. Ascendiant Capital Markets cut their target price on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Monday, June 8th.

Institutional Trading of Plus Therapeutics

An institutional investor recently bought a new stake in Plus Therapeutics stock. Citadel Advisors LLC acquired a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,597 shares of the company’s stock, valued at approximately $112,000. Citadel Advisors LLC owned approximately 0.37% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is currently owned by hedge funds and other institutional investors.

Plus Therapeutics Trading Up 6.4%

PSTV stock opened at $1.99 on Tuesday. The business’s fifty day moving average price is $3.07 and its 200 day moving average price is $4.51. Plus Therapeutics has a 12-month low of $2.90 and a 12-month high of $23.42. The company has a market capitalization of $13.70 million, a PE ratio of -0.87 and a beta of 1.40.

Plus Therapeutics (NASDAQ:PSTV) last announced its earnings results on Thursday, August 13th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.43). The firm had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $1.11 million. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. Research analysts predict that Plus Therapeutics will post -3.76 EPS for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive agents directly to tumors while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposome, also known as 186RNL or RNL. The treatment uses nanoliposomes to encapsulate the radioisotope rhenium-186 and is being evaluated for cancers affecting the central nervous system, including recurrent glioblastoma and leptomeningeal metastases.